AVIR (Atea Pharmaceuticals) Volatility: 38.62% (As of Jun. 24, 2026)


AVIR Atea Pharmaceuticals Inc AVIR
24 GF Score
Price $4.47
! 3 Warning Signs
View Full Analysis

What is Atea Pharmaceuticals Volatility?

Atea Pharmaceuticals AVIR -0.11% 24 Volatility is 38.62% as of Jun. 24, 2026. GuruFocus rates AVIR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-06-24), Atea Pharmaceuticals's Volatility is 38.62%.

Atea Pharmaceuticals  (NAS:AVIR) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Atea Pharmaceuticals Volatility Related Terms

AVIR vs IMRX, PROK, NWBO: Volatility Comparison

For the Biotechnology subindustry, Atea Pharmaceuticals's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atea Pharmaceuticals Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atea Pharmaceuticals's Volatility distribution charts can be found below:

* The bar in red indicates where Atea Pharmaceuticals's Volatility falls into.


AVIR
24GF Score
Atea Pharmaceuticals Inc AVIR
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atea Pharmaceuticals  (NAS:AVIR) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 38.62% mean?
Atea Pharmaceuticals (AVIR) has a Volatility of 38.62% as of Jun. 24, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Atea Pharmaceuticals and its competitors.
Is Atea Pharmaceuticals' Volatility too high?
Atea Pharmaceuticals' current Volatility is 38.62%. Overall, Atea Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Atea Pharmaceuticals' Volatility compare to IMRX and PROK?
Atea Pharmaceuticals' Volatility of 38.62% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Atea Pharmaceuticals and its competitors. Atea Pharmaceuticals's current Volatility is 38.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atea Pharmaceuticals stock overvalued right now?
Atea Pharmaceuticals (AVIR) has a current Volatility of 38.62%. The current Volatility is 38.62%. Atea Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Atea Pharmaceuticals (AVIR), the current Volatility is 38.62% as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atea Pharmaceuticals Business Description

Address 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
24GF Score

Get the complete analysis for AVIR

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.47
Price